Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting
In our simulation study, evolocumab 140 mg Q2W resulted in similar (versus alirocumab 150 mg Q2W) or better cost-effectiveness in achieving 2019/2025 ESC/EAS LDL-C targets for secondary prevention patients compared to other LLTs.
Authors
- J Lozano
- Francisco Torres-Bondia
- Mónica Climente Martí (ORCID: https://orcid.org/0000-0002-4387-1987)
- Xandra García‐González (ORCID: https://orcid.org/0000-0002-6269-7953)
- Vanessa Gómez-Navarro
Institutions
- Amgen (United States) (US)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitário de Santa Maria (BR)
- Hospital Universitario Doctor Peset (ES)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1080/13696998.2025.2575456
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00